Prothena’s CEO Presents at NEOD001 Interim Phase 1 Data Conference (Transcript)

[at Seeking Alpha] – Martin Koller Thank you, Dale. I am on Slide 6 study 001 is an on going Phase 1 trial in patients with AL Amyloidosis the primary objectives are safety, tolerability which are being a maximum tolerated … more

View todays social media effects on PRTA

View the latest stocks trending across Twitter. Click to view dashboard

See who Prothena is hiring next, click here to view